Results 271 to 280 of about 122,145 (339)

Glucagon-Like Peptide-1 Receptor Agonists as a Non-surgical Alternative to Bariatric Surgery for Weight Loss: A Review. [PDF]

Cureus
Steven C, Skylynn T, Bardya H, Megha B, Helen V, Lee D, Entabi F, Pemminati S.   +7 more
europepmc   +1 more source

Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists.

JAMA
Klebanoff MJ, Li P, Long JA, Doshi JA.
europepmc   +1 more source

The GLP‐1 Receptor Agonist Paradox in Dermatology: Why We Cannot Afford the Knowledge Gap

International Journal of Dermatology, EarlyView.
Ramy Awadalla, Derek Davies
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.

JAMA Netw Open
Hsiao FC, Hsu TJ, Hsieh YJ, Tung YC, Chen DY, Lin CP, Chen SW, Chu PH.   +7 more
europepmc   +1 more source

Correction to "Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review". [PDF]

J Obes
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Glucagon-like Peptide-1 Receptor Agonists

Stroke Revisited, 2021
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
J. Jeon, H. Kim
semanticscholar   +2 more sources

Glucagon-like peptide-1 receptor agonists

, 2016
Native glucagon-like peptide-1 (GLP-1) is not practical for therapeutic use due to a short half-life caused by ubiquitous, fast, and effective in vivo degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
B. Gallwitz
semanticscholar   +2 more sources

Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?

Circulation
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery.
Jennifer Linge, Andreas L. Birkenfeld, I. Neeland   +2 more
semanticscholar   +3 more sources